Lexicon Pharmaceuticals (LXRX) Other Non-Current Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Other Non-Current Liabilities data on file, last reported at $6.4 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $6.4 million, up 20.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (up 20.33% YoY), and the FY2025 annual result was $7.2 million, up 3.61% from the prior year.
• Other Non-Current Liabilities declined to $6.4 million in Q1 2026 per LXRX's latest filing, from $7.2 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $7.5 million in Q3 2025 and troughed at $1.0 million in Q2 2022.
• A 5-year average of $5.4 million and a median of $5.5 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities plunged 38.3% in 2022, then surged 447.11% in 2023.
• A 5-year view of Other Non-Current Liabilities shows it stood at $5.4 million in 2022, then fell by 2.93% to $5.3 million in 2023, then jumped by 31.51% to $6.9 million in 2024, then advanced by 3.61% to $7.2 million in 2025, then fell by 11.05% to $6.4 million in 2026.
• Business Quant data shows LXRX's Other Non-Current Liabilities at $6.4 million in Q1 2026, $7.2 million in Q4 2025, and $7.5 million in Q3 2025.